Member Info for sellonnews

From the 2,565,720,000 in issue? .

It might have a relationship to the proposed US IPO. It wouldn't surprise me if the placing price is based at or around a nominal 3p. Time will tell. .

KMK did file it: http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/KMK/12918219.html .

I sincerely hope that they aren't tempted to reduce the holding any time soon - not even as a book-keeping exercise! .

Hi trader-mick On the basis of the quote below, it is believed that subsequent to the MTFB IPO AMP's holding will be worth in excess of their total liabilities - time will tell! "We are not currently aware of any other company developing DHFRis clinical development for antibacterial use. Other companies are developing antibiotics that are not DHFRis and that work differently from our compounds. For example, Durata Therapeutics, Inc. developed and gained approval for dalbavancin and The Medicines Company developed and gained approval for oritavancin. Both antibiotics are glycopeptides, the same class as vancomycin, one of the most commonly prescribed antibiotics" Read more: http://www.nasdaq.com/markets/ipos/company/motif-bio-plc-998919-81297#ixzz4GBzxvuu4 .

Of which AMP owns approx. 25% (£16m) AMP mcap £7.90m .

https://search.rpxcorp.com/lit/madce-140817-datatern-v-microstrategy

Docket filed 07/07/2016 - unable to view on Pacer. .

Alternatively, perhaps, get into AMP, await rerate, sell, and go into MTFB with gains? . Decisions, decisions.

" Following the completion of this offering, the Amphion Group and Invesco Asset Management Limited with beneficially own approximately 24.1% and 25.4% of our outstanding ordinary shares, respectively" MTFB Share Price 53.5p AMP Share Price 3.375p Rerating due? .

From MTFB, Thursday 23.11pm "General Information Business: (Note – public offering: “Our ordinary shares are currently listed on the AIM Market of the London Stock Exchange, or AIM, under the symbol “MTFB.” On July 25, 2016, the last reported sale price of our ordinary shares on the AIM was £0.4725 per share, equivalent to a price of $0.6209 per share, assuming an exchange rate of £1.00 to $1.314, and $12.42 per ADS.”) We are a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. The discovery of new antibiotics has not kept pace with the increasing incidence of resistant, difficult-to-treat bacteria. One of the biggest threats of antibiotic resistance is from MRSA, a leading cause of hospital-acquired infections and a growing cause of infections in healthy people in the general community. Industry: PHARMACEUTICAL PREPARATIONS Employees: 4 Founded: 2009 Contact Information Address 125 Park Avenue 25th Floor, Suite 2622, New York, NY 10011, US Phone Number (212) 210-6248 Web Address http://www.motifbio.com View Prospectus: Motif Bio plc Financial Information Market Cap $102.2mil Revenues $0.0 mil (last 12 months) Net Income $-14.5 mil (last 12 months) IPO Profile Symbol MTFB Exchange NASDAQ Shares (millions): 2.8 Price range $12.42 - $12.42 Est. $ Volume $34.8 mil Manager / Joint Managers SunTrust Robinson Humphrey/ Ladenburg Thalmann CO-Managers - Expected To Trade: 8/4/2016 Day: Friday Quiet Period Expiration Date: Available only to Subscribers Lock-Up Period Expiration Date: Available only to Subscribers SCOOP Rating Available only to Subscribers Rating Change Available only to Subscribers"

Owning 26.08% of MTFB - looking good. .

It would appear that the price is being tightly controlled in advance of the NASDAQ IPO. .

It's the Year-on-Year increase. As to the Interims: "Motif's share price rose sharply from 20 pence at the IPO to 68.75 pence at the end of the reporting period. As a result, the value of Amphion's holdings in Motif rose from US $13.2 million at the end of December to US $46.5 million at the end of June. During the Period, the share price of Kromek also recovered, from 34 pence to 43 pence at the end of June. These two changes, combined with the reduction in total liabilities over the period, were the main factors behind the substantial improvement in Amphion's Net Asset Value per Ordinary Share, over the Period, to 12.3 pence at the end of June. While the prices of both Motif and Kromek have fallen back since the end of June, the pro-forma NAV per Ordinary Share is currently approximately 10 pence per Ordinary Share."

http://www.londonstockexchange.com/exchange/news/alliance-news/detail/1466672512610636800.html .

This is relevant: "Vivo Capital, a current Shareholder of the Company, is acting as a cornerstone investor in relation to the US Placing and is expected to act as a cornerstone investor in Tranche 2" Check: "Cornerstone Investor" .

The clock starts ticking on July 29, as the Placing is a foregone conclusion - please see Circular! "The Company has agreed to use its commercially reasonable efforts to consummate the US IPO as promptly as possible and no later than 180 days following Admission, or by such later date as may be agreed by the Company and Placees holding a majority of the US Units issued in the US Placing." .

Absolutely, Hardman's 19p price is on the horizon. .

On 2,150 shares purchased - the spread is very large.

Was wondering why the price flat-lined all day after 11am, herein is a possible explanation - order filling. Be interesting to see if the "brakes" come off today. .